USPTO serial 97646050
AIONCO
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- —
- Examiner
- ROCHA, CAMERON R
- Law office
- TMO LAW OFFICE 118- EXAMINING ATTORNEY ASSIGNED
What this means
These status codes mean the trademark application is abandoned and no longer pending. Common reasons include missing an Office Action response (600), filing without a valid basis (602), express abandonment by the applicant (604), or failure to respond to an examiner's inquiry (618). Revival may be possible in limited circumstances. If abandonment was unintentional, consult counsel about a petition to revive. Otherwise file a new application if protection is still needed.
Need help with AIONCO?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Andrew J. Gray IV
Andrew J. Gray IV MORGAN, LEWIS & BOCKIUS LLP1400 PAGE MILL ROADPALO ALTO, CA 94304United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Medical testing products, namely, modified immune cells; Medical testing products, namely, modified immune cells for use in connection with various cancers with genetic treatments | ACTIVE | — |
| 009 | Downloadable software and mobile applications for genetic assessment and identification of cancer, cancer ailments, and cancer mutations for scientific, medical, diagnostic, treatment, and research purposes, for creating local databases of genomic sequences, cancer ailments, and cancer mutations for tracking, matching, searching, testing, aggregating, researching, and diagnosing cancer, cancer ailments, and cancer mutations, for creating, accessing, and using online databases of genomic sequences, cancer ailments, and cancer mutations for tracking, matching, searching, testing, aggregating, researching, and diagnosing cancer, cancer ailments, and cancer mutations, for recording, analyzing, storing, manipulating and organizing genetic and molecular data, and for providing access to multiple online databases that contain aggregated results of molecular biology testing and genotyping; medical testing products, namely, downloadable vaccination test forms | ACTIVE | — |
| 010 | Medical testing and treatment products in the form of treatment therapies, namely, apparatus for medical diagnosis, drug delivery apparatus and genetic delivery apparatus all for various cancers with genetic treatments and specimen collection tubes and containers for collecting patient specimens, namely, blood, urine, saliva, and tissue, for genomic sequencing and for detection of gene mutations, gene expression profiles or other molecular indicators or markers associated with cancer or risk of developing cancer; Medical testing and treatment product kits containing blood specimen collection tubes and containers for collecting patient blood specimens for genomic sequencing and detection of gene mutations, gene expression profiles or other molecular indicators or markers associated with cancer or risk of developing cancer modified immune cells and treatment therapies, and also containing modified immune cells, treatment therapies, test forms, mailing materials and user information inserts | ACTIVE | — |
| 016 | Medical testing and treatment products, namely, printed test forms and printed user information inserts for medical products; Medical testing products, namely, printed vaccination test forms | ACTIVE | — |
| 042 | Providing online non-downloadable software and software programs for genetic assessment and identification of cancer, cancer ailments, and cancer mutations for scientific, medical, diagnostic, treatment, and research purposes, for creating online databases of genomic sequences, cancer ailments, and cancer mutations for tracking, matching, searching, testing, aggregating, researching, and diagnosing cancer, cancer ailments, and cancer mutations, for creating, accessing, and using online databases of genomic sequences, cancer ailments, and cancer mutations for tracking, matching, searching, testing, aggregating, researching, and diagnosing cancer, cancer ailments, and cancer mutations, for recording, analyzing, storing, manipulating and organizing genetic and molecular data, and for providing access to multiple online databases that contain aggregated results of molecular biology testing and genotyping | ACTIVE | — |
| 044 | Providing medical diagnostic and treatment services, namely, tumor detection in the form of a liquid biopsy; medical diagnostic and treatment services in the nature of tumor analysis, diagnosis, and identification in the form of sequenced tissue identification, and tumor medical treatment therapy in the form of identification of appropriate combination of mutations for targeted cancers and identification of appropriate treatments targeted for those combination of mutations via modified T-Cells in the form of other treatments to inhibit expressions of those combination of mutations and to modify one or more of the mutations in the combination | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Avellino Lab USA, Inc.
- Other trademarks in Class 005
- Other trademarks in Class 009
- Other trademarks in Class 010
- Other trademarks in Class 016
- Other trademarks in Class 042
- Other trademarks in Class 044
- Similar marks named AIONCO
- Prosecution event MAB2 explained
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Mar 15, 2024 | MAB2 | ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND | The trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time. |
| Mar 15, 2024 | ABN2 | ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE | The trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time. |
| Nov 10, 2023 | XELG | APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED | — |
| Nov 10, 2023 | XELR | APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED | — |
| Aug 11, 2023 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Aug 11, 2023 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Aug 11, 2023 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Aug 7, 2023 | DOCK | ASSIGNED TO EXAMINER | — |
| Nov 9, 2022 | MDSC | NOTICE OF DESIGN SEARCH CODE E-MAILED | — |
| Nov 8, 2022 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Oct 27, 2022 | NWAP | NEW APPLICATION ENTERED | — |